- JP-listed companies
- Perseus Proteomics Inc.
- Income statement
Perseus Proteomics Inc. (4882) Income statement
Market cap
¥3.3B
P/E ratio
Perseus Proteomics develops high-performance antibodies for cancer treatment and drug discovery using proprietary technology from the University of Tokyo.
| 2016/03 | 2017/03 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | |
| Revenue | 570 | 283 | 304 | 276 | 86 | 68 | 72 | 94 | 100 | 120 |
| Revenue growth (%) | - | |||||||||
| Cost of revenue | - | - | - | 19 | 6 | 4 | 4 | 8 | 13 | 16 |
| Gross profit | - | - | - | 257 | 79 | 64 | 68 | 87 | 88 | 104 |
| Gross margin (%) | - | - | - | |||||||
| Operating margin (%) | - | - | - | |||||||
| Operating expenses | - | - | - | 402 | 892 | 476 | 540 | 784 | 982 | 930 |
| Operating income | - | - | - | -145 | -812 | -412 | -472 | -698 | -895 | -826 |
| Income before tax | 172 | -197 | -164 | -146 | -834 | -410 | -482 | -690 | -879 | -830 |
| Pretax margin (%) | 30.1 | -69.9 | -53.8 | -52.7 | -972.9 | -603.6 | -669.6 | -732.1 | -875.9 | -689.4 |
| Provision for income taxes | - | - | - | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| Effective tax rate (%) | - | - | - | |||||||
| Net income | 155 | -188 | -178 | -163 | -842 | -413 | -599 | -787 | -1,104 | -905 |
| Net income margin (%) | ||||||||||
| Earnings per share | 1,812.53 | -2,203.93 | -2,072.47 | -26.53 | -136.95 | -59.03 | -54.47 | -66.93 | -93.69 | -63.41 |
| Dividend per share | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | |||||||
| EBITDA margin (%) | - | - | - |